Safety & Pharmacokinetic Study of IMM0306 in Patients With Refractory or

Updated 06/21/2024

Status Suspended

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04746131
Study type	Interventional
Source	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Contact
Status	Suspended
Phase	Phase 1
Start date	January 15, 2021
Completion date	April 11, 2024

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00588094` - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL	Phase 2
	Not yet recruiting	`NCT05091541` - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
	Recruiting	`NCT03639181` - Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)	Phase 2
	Recruiting	`NCT06104553` - A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma	Phase 1/Phase 2
	Terminated	`NCT01352312` - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma	Phase 1
	Not yet recruiting	`NCT05771883` - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide	Phase 1/Phase 2
	Not yet recruiting	`NCT06314828` - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL	Phase 1
	Enrolling by invitation	`NCT05332054` - Long-Term Follow-up Study
	Suspended	`NCT04697290` - CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.	Early Phase 1
	Completed	`NCT02564744` - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL	Phase 2
	Recruiting	`NCT05453669` - Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL	Phase 1
	Recruiting	`NCT05190068` - HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 1
	Active, not recruiting	`NCT00927797` - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)	Phase 2
	Recruiting	`NCT05436223` - Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma	Phase 2
	Completed	`NCT00457782` - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma	Phase 1
	Not yet recruiting	`NCT03105596` - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)	Phase 2